Kiribati vs Serbia: Burden of disease
Kiribati
50,666 DALYs per 100,000 people
in 2021
Serbia
50,050 DALYs per 100,000 people
in 2021
Kiribati rank
28th
Serbia rank
30th
Burden of disease over time
- Kiribati
- Serbia
How they compare
Kiribati currently reports 50,666 DALYs per 100,000 people against 50,050 DALYs per 100,000 people in Serbia, a difference of 616 DALYs per 100,000 people.
Across all 22 years both countries report, Kiribati has been ahead every year.
Kiribati ranks 28th and Serbia ranks 30th of 194 countries.
Kiribati has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Kiribati | Serbia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 49,784 DALYs per 100,000 people | 41,712 DALYs per 100,000 people | 8,071 DALYs per 100,000 people | Kiribati |
| 2010s | 49,478 DALYs per 100,000 people | 40,191 DALYs per 100,000 people | 9,287 DALYs per 100,000 people | Kiribati |
| 2020s | 49,598 DALYs per 100,000 people | 47,225 DALYs per 100,000 people | 2,374 DALYs per 100,000 people | Kiribati |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher burden of disease, Kiribati or Serbia?
- Kiribati, at 50,666 DALYs per 100,000 people against 50,050 DALYs per 100,000 people in Serbia as of 2021.
- What is the difference in burden of disease between Kiribati and Serbia?
- 616 DALYs per 100,000 people, with Kiribati ahead.
- How many years of comparable data are there for Kiribati and Serbia?
- 22 years are reported by both, from 2000 to 2021.
- How do Kiribati and Serbia rank globally for burden of disease?
- Kiribati ranks 28th and Serbia ranks 30th of 194 countries.
- Where does this data come from?
- World Health Organization (2024) – with major processing by Our World in Data, published as Burden of disease. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated number of DALYs from all causes in both sexes, per 100,000 people.